Italian Covid-19 candidate vaccine shows 99% antibody response
Rome, Jul 12 (EFE).- Italian biotech company ReiThera Srl announced Monday its preliminary data from its Covid-19 candidate vaccine shows a 93% antibody response after the first dose and 99% after the second dose.
“We are very excited about the preliminary Phase 2 data from our COVITAR trial,” said Roberto Camerini, MD Reithera Medical Director.
The study was conducted in 24 clinical centers across Italy and enrolled 917 volunteers over the age of 18, the company said.
The trials showed SARS-CoV-2 spike protein after five weeks were comparable to those measured in groups of people recovering from Covid-19, it added.
Preliminary data also showed that side effects from the vaccine were mild and of short duration, including pain at the injection site, fatigue and muscle pain.
After these positive results, experts and advisory boards have recommended the continuation of the development of COVITAR.
Some 23.8 million people have received the full course of the Covid-19 vaccine in Italy, equivalent to around 44 percent of the population over 12 years of age. EFE